Flecainide

Таблетки By prescription

Antiarrhythmic drug, IC class

Flecainide

Indications

Flecainide is indicated for the prevention and treatment of cardiac rhythm disorders in adult patients over 18 years of age without left ventricular dysfunction:

- documented symptomatic paroxysmal supraventricular tachycardia, including atrioventricular (AV) nodal reciprocal tachycardia or supraventricular tachycardia associated with the presence of additional conduction pathways (e.g., in Wolff-Parkinson-White syndrome);

- paroxysmal atrial fibrillation or flutter accompanied by disabling symptoms;

- documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia.

Flecainide may be used to maintain normal heart rhythm after it has been restored by other antiarrhythmic agents.

Contraindications

Do not take the drug if you are

- allergic to flecainide or any other components of the drug

- asymptomatic or non-life-threatening ventricular arrhythmias

- cardiogenic shock, heart failure

- acute myocardial infarction

- history of myocardial infarction (except for life-threatening ventricular arrhythmias)

- significantly reduced blood pressure (severe arterial hypotension)

- infrequent heartbeat (bradycardia), slow irregular heartbeat with skipped beats (sinus node weakness syndrome) or alternation of periods of slow heartbeat with periods of rapid heartbeat (bradycardia-tachycardia syndrome, unless a pacemaker is installed)

- contractility of the heart muscle is reduced and your heart is unable to pump as much blood as your body needs (cardiogenic shock, heart failure)

- various intracardiac conduction disorders (AV block of II-III degree or sinoatrial block (in the absence of an implanted pacemaker), Hiss bundle branch block or distal intraventricular conduction disorders)

- long-term (permanent) atrial fibrillation (atrial fibrillation)

- brugada syndrome (a genetic disorder in apparently healthy individuals that causes life-threatening heart rhythm disturbances and is accompanied by electrocardiogram changes)

- a valve heart defect that significantly impairs blood flow in the heart (intracardiac haemodynamics)

- class I antiarrhythmic drugs (e.g., propafenone, etomosine, etacizine) have already been prescribed

- the balance of salts and ions in the body is significantly disturbed (electrolyte disturbances).

If you think that any of the above applies to you, please inform your doctor.

Usage

Inside. The break line is drawn only to facilitate breaking the tablet if it is difficult to swallow it whole, not to divide it into equal doses.

It is recommended to swallow the tablet whole, without chewing or swallowing.

Therapy with Flecainide should be performed only under the supervision of a physician experienced in the treatment of arrhythmias.

Download full instruction

Report undesirable reaction

If you have information about undesirable reaction after taking the drug

Hotline +7 (495) 984-28-47

Report

Have questions? Contact Us

Has contraindications. Needs specialist overview.

Please read our privacy policy

The present personal data processing policy is drawn up in accordance with the requirements of the Federal Law of July 27, 2006. No. 152-FЗ “On Personal Data” and determines the procedure for processing personal data and measures to ensure the security of personal data of Mir-Pharm LLC (hereinafter referred to as the Operator).

The operator sets as his most important goal and condition for the implementation of his activities the respect for the rights and freedoms of man and citizen in the processing of his personal data, including the protection of the rights to privacy, personal and family confidentiality.

The Operator's policy regarding the processing of personal data (hereinafter - the Policy) applies to all information that the Operator can receive about visitors of the website https://mirpharm.ru.

The user can get any clarification on issues of interest regarding the processing of his personal data by contacting the Operator via e-mail info@mirpharm.ru.

The current version of the Policy is located in free access on the Internet at https://mirpharm.ru/policy.

This document will reflect any changes in the policy of processing personal data by the Operator. The policy is valid indefinitely until it is replaced with a new version.